Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends

AbbVie has raised its dividend for 53 consecutive years and yields 2.4%; earning $5,000 annually in dividends would require 723 shares costing about $206,358 at the time of writing. Its shares gained 93% over three years as Skyrizi and Rinvoq helped offset Humira’s loss of U.S. exclusivity, while Pfizer shares fell 8% amid fading COVID-19 vaccine sales and patent cliffs. The article presents AbbVie as a potential long-term income investment despite its lower yield than Pfizer’s.

Analysis

The key distinction is dividend quality, not headline yield. A larger payout from PFE is not automatically better income: the market may be pricing greater uncertainty around replacement revenue and cash-flow durability. For ABBV, the underwriting question is whether newer products can sustain growth as Humira erosion continues—not whether its dividend record alone limits downside. A yield below Treasuries also means ABBV must justify equity, patent-cycle, and product-concentration risk through earnings growth; it is not a bond substitute.

Near term, the article offers little new fundamental evidence to support chasing ABBV after substantial relative outperformance. Over 1–3 months, watch reported growth and guidance for Skyrizi and Rinvoq, Humira erosion, and each company's dividend coverage and cash generation. Over 6–18 months, the main risk is that ABBV's replacement growth disappoints or pricing/access pressure reduces the value of its newer portfolio; the contrarian risk is that investors over-extrapolate PFE's weak period if its revenue replacement and cash-flow metrics improve. The article provides no payout coverage, valuation comparison beyond ABBV's cited multiple, or updated guidance, so a yield-based ranking is not enough to establish relative value.

Key Decisions for Investors

• Do not add ABBV solely to target a dividend-income number; compare its current cash-flow coverage and forward earnings outlook with the risk-free alternative, and size it as an equity exposure rather than a fixed-income substitute.
• Treat long ABBV / short PFE as a watch-list pair, not an immediate high-conviction trade: initiate only after checking relative valuation, dividend coverage, and current guidance. Reassess if ABBV's newer-product growth or Humira erosion materially misses guidance, or if PFE demonstrates durable revenue replacement and improving cash generation.
• For the next earnings cycle, track Skyrizi/Rinvoq growth, Humira erosion, and dividend coverage at ABBV; track revenue replacement and cash generation at PFE. These are the falsifiers for the respective income and relative-performance theses.
• Avoid interpreting the article's stated yield comparison as a complete risk-adjusted return case; verify the applicable Treasury yield and current company data before acting, since the article does not establish those inputs or the sustainability of either payout.